Cleo Diagnostics (ASX.COV) Appoints U.S.-based Dr Nicholas Lambrou as Key Opinion Leader
By API User
Highlights CLEO appoints its first U.S. Key Opinion Leader, Dr Nicholas Lambrou, a leading gynaecologic oncologist and surgical specialist Dr Lambrou to support clinical advocacy, publication development, and presentation of CLEO’s technology at major U.S. scientific meetings KOL engagement represents a key U.S. market entry activity as a part of CLEO’s commercialisation strategy for its Pre … Continued